Myelodysplastic syndromes moving towards personalized management by Eva

Myelodysplastic syndromes: moving towards personalized management by Eva Hellström-Lindberg, Magnus Tobiasson, and Peter Greenberg haematol Volume 105(7): 1765 -1779 July 1, 2020 © 2020 by Ferrata Storti Foundation

Morphological manifestations of dysplasias (WHO 5. 01 and 6. 02). *. Eva Hellström-Lindberg et al. Haematologica 2020; 105: 1765 -1779 © 2020 by Ferrata Storti Foundation

Chronology of the terminology for myelodysplastic syndromes. Eva Hellström-Lindberg et al. Haematologica 2020; 105: 1765 -1779 © 2020 by Ferrata Storti Foundation

World Health Organization classification of myelodysplastic syndrome. Eva Hellström-Lindberg et al. Haematologica 2020; 105: 1765 -1779 © 2020 by Ferrata Storti Foundation

Pathogenesis of myelodyspastic syndromes: underlying mechanisms. Eva Hellström-Lindberg et al. Haematologica 2020; 105: 1765 -1779 © 2020 by Ferrata Storti Foundation

Mutations in myelodysplastic syndromes. Eva Hellström-Lindberg et al. Haematologica 2020; 105: 1765 -1779 © 2020 by Ferrata Storti Foundation

Clinical outcomes of patients with myelodysplastic syndrome in relation to Revised International Prognostic Scoring System prognostic risk-based categories. Eva Hellström-Lindberg et al. Haematologica 2020; 105: 1765 -1779 © 2020 by Ferrata Storti Foundation

Causes of cytopenia and/or dysplasia other than myelodysplastic syndromes. Eva Hellström-Lindberg et al. Haematologica 2020; 105: 1765 -1779 © 2020 by Ferrata Storti Foundation

Therapeutic options for myelodysplastic syndrome. Eva Hellström-Lindberg et al. Haematologica 2020; 105: 1765 -1779 © 2020 by Ferrata Storti Foundation